OBJECTIVE: To investigate associations between statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD). METHODS: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties. RESULTS: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (>or=5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin. CONCLUSION: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
OBJECTIVE: To investigate associations between statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD). METHODS: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties. RESULTS: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (>or=5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin. CONCLUSION: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
Authors: Gail A Kang; Jeff M Bronstein; Donna L Masterman; Matthew Redelings; Jarrod A Crum; Beate Ritz Journal: Mov Disord Date: 2005-09 Impact factor: 10.338
Authors: Xuemei Huang; Alvaro Alonso; Xuguang Guo; David M Umbach; Maya L Lichtenstein; Christie M Ballantyne; Richard B Mailman; Thomas H Mosley; Honglei Chen Journal: Mov Disord Date: 2015-01-14 Impact factor: 10.338
Authors: Tammy A Butterick; Urule Igbavboa; Gunter P Eckert; Grace Y Sun; Gary A Weisman; Walter E Müller; W Gibson Wood Journal: Mol Neurobiol Date: 2010-04-06 Impact factor: 5.590
Authors: Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg Journal: J Neurol Date: 2014-07-25 Impact factor: 4.849